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Abstract. Although artemisinin-based combination therapies (ACTs) are widely viewed as safe drugs with a wide
therapeutic dose range, concerns about neuroauditory safety of artemisinins arose during their development. A decade
ago, reviews of human data suggested a potential neuro-ototoxic effect, but the validity of these findings was questioned.
With 5–10 years of programmatic use, emerging artemisinin-tolerant falciparum malaria in southeast Asia, and the first
calls to consider an increased dose of artemisinins, we review neuroauditory safety data on ACTs to treat uncomplicated
falciparum malaria. Fifteen studies reported a neurological or auditory assessment. The large heterogeneity of neuro-
ototoxic end points and assessment methodologies and the descriptive nature of assessments hampered a formal meta-
analysis and definitive conclusions, but they highlight the persistent lack of data from young children. This subgroup is
potentially most vulnerable to any neuroauditory toxicity because of their development stage, increased malaria suscep-
tibility, and repeated ACT exposure in settings lacking robust safety monitoring.
BACKGROUND
Over the past decade, artemisinin-based combination
therapies (ACTs) have been deployed as first- and second-
line treatments for uncomplicated malaria across malaria-
endemic regions. Since 2001, this deployment has included
the delivery of over 500 million treatments of artemether-
lumefantrine (AL), making it one of the most widely pre-
scribed drugs worldwide.1
Artemisinin derivatives are generally viewed as safe drugs
with a very wide therapeutic dose range. However, a number
of animal studies conducted before the wide deployment of
artemisinins identified their potential ototoxic effects targeting
mainly the auditory and vestibular pathways. Damage to spe-
cific brainstem nuclei was reported when administering high
and parenteral doses of the lipophilic artemisinin molecules
arteether and artemether.2–8 A drug treatment safety study
in rats showed the drugs’ toxicities during a critical neuro-
developmental stage and their potential long-term cumulative
effect.9 This study showed that repeated treatment (up to eight
cycles) with lower parenteral doses of B-arteether (5–10 mg/kg)
was associated with brainstem damage after five cycles,
whereas higher single doses (60–90 mg/kg) caused death with-
out brainstem pathology.9 These findings suggest that repeated
treatment of these oil-based artemisinin components could
cause similar neurological and ototoxic damage in young chil-
dren. It was argued that the implications for the use of ACTs
in humans were not clear because of the use of lower doses,
the use of more water-soluble compounds, and the largely
oral route of administration. In programmatic settings, where
malaria incidence is highest among the youngest children,
individual doses of 5–10 mg/kg will occur where ACTs are
dosed by age rather than weight. The possibility of cumulative
ototoxicity with repeated use and the specific risk in sub-
groups that could be exposed to doses over 5 mg/kg have not
been investigated.
Given the considerable number of trials in children 6–
59 months of age and their wide-scale use in control programs,
one might assume that any specific safety concerns would have
been previously identified, which is not necessarily the case.
Standard phase III trials generally use the drug of interest at
the target dose during a single or a low number of exposures,
and they are underpowered for safety end points. Furthermore,
there are no standardized guidelines to evaluate ACT ototox-
icity or neurotoxicity in clinical trials, both of which are more
challenging to assess in young children. Without specific encour-
agement or recommendation of neuroauditory assessments, few
research teams voluntarily opt to conduct such assessments.
Pharmacovigilance conducted as part of phase IV or post-
marketing safety monitoring largely depends on passive detec-
tion of adverse events within regular healthcare systems that
often lack the capacity to diagnose changes in auditory function.
Over the past decades, there has been a considerable
increase in the reported prevalence of hearing impairment
worldwide. This increase has been attributed to better case
finding, ageing populations, an increase in noise-induced
hearing loss, excessive use of ototoxic drugs, and untreated
otitis media.10 Two-thirds of the cases are from low-income
countries, where preventable factors are still the leading cause
(World Health Organization [WHO], unpublished data). Data
on drug-induced hearing impairment again rely predominantly
on relatively weak pharmacovigilance systems. Hearing impair-
ment may not be commonly attributed to recently used drugs,
resulting in underreporting. Case reports of hearing loss caused
by the use of potentially ototoxic drugs are complicated fur-
ther by the use of concomitant and different ototoxic drugs
over time.
Techniques, such as otoacoustic emissions (OAEs), electroco-
chleography, and auditory brainstem responses (ABRs), have
been used for detecting and monitoring ototoxicity in infants
and non-responsive subjects with success.11,12 Among these
techniques, ABR is viewed as the most objective and sensitive
method capable of exploring the specific brainstem damage
pattern formed by ACTs; the exact clinical implication of
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changes in the responses is, however, still not known.13 To
assure quality ABR testing, methods are required to rule out
external or middle ear disease. Tympanometry provides
functional and quantitative information about the middle
ear, and its use has been recommended combined with quali-
tative data provided by otoscopy. Nevertheless, its interpreta-
tion and reliability are equivocal in infants because of a highly
compliant ear canal.14 Otoscopy alone, however, allows for
the prompt detection of ear canal and middle ear (tympanic
membrane) abnormalities before ABR performance, even by
non-medically qualified staff, and therefore, it is a feasible
tool in low-resource settings.15
In 2004, a study from Mozambique suggested that AL
(Coartem, Novartis Pharma AG, Basel, Switzerland) was
associated with hearing impairment in adults being treated
for uncomplicated malaria.16 Although this reopened a
global debate on ACT safety, most attention focused on
the design weaknesses of the study, detracting from a valid
attempt to highlight the need to exclude any safety concerns
systematically. Ten years after this debate, we present an
update of the published literature on available safety data of
ACTs regarding neuro-ototoxicity when treating uncompli-
cated malaria and identify remaining knowledge gaps.
METHODS
Search strategy. A search of electronic databases was con-
ducted to identify publications on the treatment of uncompli-
cated malaria with ACTs that included specific reports on
neuroauditory safety outcomes. Exclusion criteria were no
inclusion of neuroauditory or neurological safety outcomes,
studies on treatment of severe malaria, pre-clinical studies,
reviews, case reports, and expert opinions. There was no
exclusion regarding participants, interventions, comparisons,
overall outcomes, or study design.
The search was not limited by language or year, and
it was carried out using the databases of EMBASE and
PubMed MEDLINE. The latest search was conducted in
January of 2013. The search strategy included seven different
MeSH medical subject headings (MeSH) term combinations:
artemisinin combination therapy and safety, artemisinins and
uncomplicated malaria and safety, artemisinins and audi-
tory safety, artemisinins and neurological safety, artemisinins
and ototoxicity, artemisinins and neurological assessment, and
artemisinins and hearing assessment.
Neuroauditory and/or neurological assessment methods.
Methods currently recommended for auditory measurements
Table 1
Summary table of auditory methods of assessment in infants and children
Developmental age Auditory test (time per test) Type of conventional measurement Strengths Limitations and notes
Physiologic or electrophysiologic tests
All ages Otoacoustic emissions
(10-minute test)
Cochlear (outer hair cells)
response to presentation
of a stimulus
Ear-specific results; not
dependent on whether
patient is asleep or awake;
quick test time. It is a
valuable screening method.
Infant/child must be relatively
inactive during the test;
not a true test of hearing,
because it does not assess
cortical processing of sound.
It only tests the function of
the cochlear amplifier.
Damage of the cochlear
amplifier results in hearing
loss of approximately 40 dB.
Birth to
9 months
Auditory brainstem responses
(15-minute test)*
Activity in auditory nerve
and brainstem pathways
after conventional (1–
4 kHz) click stimulus or
tone burst
Ear-specific results; responses
not dependent on patient
cooperation. Detects
clinically significant effects
that affect speech (1–4 kHz)
and can interfere in
neurodevelopment.
Infant or child must remain
quiet during the test.
Behavioral tests
9 months to
2.5 years
COR or VRA
(30-minute test)
Responses to speech and
frequency-specific
stimuli presented
through speakers
Assesses auditory perception
of child
Assesses hearing of the
better ear (not ear-specific);
cannot rule out unilateral
hearing loss. Subjective test:
results depend on the
cooperation of the patient.
2.5–4 years Play audiometry
(30-minute test)
Auditory thresholds in
response to speech and
frequency-specific
stimuli presented
through earphones and/
or bone vibrator
Ear-specific results; assesses
auditory perception of child
Attention span of the child
may limit the amount
of information obtained.
Subjective testing: results
depend on the will of
the patient.
4 years to
adolescence
Conventional audiometry
(30-minute test)
Auditory thresholds in
response to speech and
frequency-specific
stimuli presented
through earphones and/
or bone vibrator
Ear-specific results; assesses
auditory perception
of patient
Depends on the level
of understanding and
cooperation of the child.
Subjective testing: results
depend on the will of
the patient.
Modified from Cunningham and Cox.45 COR = conditioned-oriented responses; VRA= visual-reinforced audiometry.
*Fifteen minutes is very short and can only apply if a click sound is measured at a few decibel levels. It does not explore frequencies over 4 kHz (conventional click). Therefore, it cannot detect
early toxicity (ototoxic effects start in very high frequencies of 8–12 kHz). The lengths of IPLs, measured in milliseconds, are the least variable and most independent of subject stimuli and
recording parameters compared with other measures derived from ABRs.19
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in infants and children are described in Table 1. In this review,
the methods to assess neurological and neuroauditory func-
tion varied from subjective reports of hearing loss by partici-
pants or caregivers and whispered voice tests to conventional
and pure tone audiometry (PTA), OAE, and/or ABR.
Tympanometry and otoscopy were also conducted in some
studies to rule out ear canal and middle ear disease.
We included neurological and neuropsychiatric assessments
when they were reported. They were either reported as general
neurological assessments or specifically described as more
targeted, such as fine-finger dexterity, hand coordination,
audiovestibular tests (Rinne’s and Weber’s tests), and/or
behavioral–developmental assessments adapted for children
(tone and behavior—Hammersmith, Bayley). One study
reported neuropsychiatric assessments based on question-
naires to caregivers and children over 3.5 years old.
Neuro-ototoxic end points. Neuro-ototoxic end points var-
ied substantially across studies and among methodologies used.
Hearing impairment definition with audiometry.WHO grades
of hearing impairment suggest that no impairment is reported
at £ 25 dB, slight impairment is 26–40 dB, moderate impair-
ment is 41–60 dB, severe impairment is 61–80 dB, and pro-
found impairment, including deafness, is ³ 81 dB. Hearing
threshold levels are taken for the better ear as the mean of the
unaided pure tone threshold levels and the frequencies of 0.5,
1, 2, and 4 kHz (decibels). In addition, hearing threshold levels
(decibels) defining disabling hearing impairment are established
as being > 31 dB in individuals ages < 15 years and > 41 dB in
individuals ages ³ 15 years (audiometric threshold measure-
ments according to the international standards ISO 8253-1).
Ototoxicity with ABR. There are no standardized end
points to assess ototoxicity with ABR, although based on
animal studies, the wave III–V latency would most likely be
affected by artemisinin toxicity, and any cumulative drug
exposure and toxicity effect would be expected to produce a
bilateral prolongation of the I–V, I–III, and III–V interpeak
latencies (IPLs).17 Hearing failure was defined as an IPL
absolute latency in milliseconds above +2.5 SD of the mean
for age in this study. McCall and others18 looked at latencies
prolonged > 2 SD from baseline. In the study by Hutagalung
and others,19 a difference of > 0.30 milliseconds in IPLs with
age-matched controls was considered clinically significant.
Carrasquilla and others20 used a wave III latency increase of
> 0.30 milliseconds at day 7 after treatment.
Neurological end points. There were no specified pre-defined
general neurological end points in the reviewed papers, and
outcome measures consisted of description of main findings,
intensity, frequency, age distribution, onset, and resolution.
Risk of bias assessment. A structured data collection sheet
was developed to extract data from each selected study. Study
design, participants, location, auditory method of assessment,
neuro-ototoxic end points reported, and main results were
appraised. The reported data were appraised separately by
two independent assessors (V.R.M. and C.G.M.) and evalu-
ated for the risk of bias in individuals and across studies
using The Cochrane Collaboration’s tool for assessing risk of
bias in randomized and non-randomized studies combined with
the Agency for Healthcare Research and Quality (AHRQ)
2012 recommendations (Table 2).21,22
The heterogeneity of study end points andmethods prevented
any meaningful meta-analyses.
RESULTS
The literature search process is presented in Figure 1. Sixty-
eight full-text articles were assessed for eligibility to identify
specific neurological or auditory assessments that were under-
taken during the safety evaluation but were not described in
the abstract. Fifteen studies were eligible for inclusion in this
review (eight randomized controlled trials [RCTs] and seven
observational studies). Seven studies looked at multiple expo-
sures. From these multiple exposure studies, four studies
included neurological assessment (with or without auditory
assessment) in children under 5 years old, and two studies were
RCTs. Single exposures were investigated in eight studies:
three studies included children under 5 years old, and two stud-
ies were RCTs. Seven of eight single-exposure studies con-
ducted a pre-treatment neurological and/or auditory baseline
assessment, allowing pre-to-post comparison; however, only
Table 2
Risk of bias assessment of selected studies
Selection bias
Performance bias: blinding
of participants and personnel
Detection bias:
blinding
of outcome assessment
Attrition bias:
incomplete outcome
data
Reporting bias:
selective
reporting
Random sequence
generation
Allocation
concealment
RCTs
Adjei and others, 200823 + ? ? ? ? ?
Maiteki-Sebuguzi and others, 200824 − − + + + ?
Ndiaye and others, 2011 25 − − + + + ?
Benjamin and others, 201246 + − ? ? + ?
Carrasquilla and others, 201220 − − + + − ?
Abdulla and others, 200841 + + + + + +
Gurkov and others, 200827 − − NA + ? ?
Ambler and others, 200947 + + NA + ? ?
NRTs (AHRQ)
Kissinger and others, 200017 − NA − ? ? +
Van Vugt and others, 200026 ? NA ? ? − +
Toovey and Jamieson, 200416 − NA − ? ? +
Hutagalung and others, 200619 − NA − ? ? +
McCall and others, 200618 + NA ? ? ? +
Carrara and others, 200848 + NA ? ? ? +
Frey and others, 201028 ? NA + ? ? ?
The Cochrane Collaboration’s tool for assessing risk of bias in RCTs (adapted from Higgins and others21) and AHRQ recommendations (2012) for non-randomized trials (NRTs).22 NA = not
applicable; + = low risk of bias; ? = unclear risk of bias; – = high risk of bias.
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two of the multiple exposure studies did so. The pooled studies
investigated a total of 3,859 participants (including controls)
(Figure 2).
Study characteristics are summarized in Table 3, and results
of individual studies are in Table 4. Of three RCTs that
assessed efficacy and safety of multiple exposures to ACTs,
two RCTs included children under 5 years of age,23,24 and one
RCT assessed auditory safety in children ³ 12 years old.25
Exposure to several courses of ACTs in these trials was not
associated with an increased risk of neuroauditory adverse
events. However, in one RCT that included young children
conducted by Adjei and others,23 specific auditory assessments
were only conducted in older children (> 5 years old), because
the specific auditory test used relied on the cooperation and
responses of the tested individual. In this study, hearing thresh-
olds were significantly elevated in treated children compared
with those thresholds in age- and sex-matched controls without
malaria on days 0, 3, 7, and 28 but not after 9–12 months.23
Ndiaye and others25 performed audiometric measurements in
children ³ 12 years old during first and second malarial epi-
sodes (before treatment and on days 3 and 28) and found no
significant variation on hearing thresholds at any point.
Two observational retrospective case-control studies
explored the potential ototoxic effect of ACTs after multiple
exposures and included children under 5 years old. In children
older than 5 years (there were not enough controls under
5 years old to make comparisons), Kissinger and others17 and
Van Vugt and others26 showed a prolongation in the objective
ABR (longer I–III IPLs) compared with the controls without
artemisinin treatment. Post-treatment ABR prolongation
described by Kissinger and others17 was, however, only found
on the right side. Neither study could correlate those changes
Figure 1. Study selection flow diagram. PRISMA 2009 Flow Diagram.
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to the cumulative dosage of artemisinins administered over
periods of 2 and 3 years, respectively.17,26
Toovey and Jamieson16 also conducted an observational
retrospective case-control study of 300 adult participants in
Mozambique, where audiometry was performed on construc-
tion site workers at the start of employment and after repeated
diagnosis of malaria and prescription with AL (N = 150). These
individuals were compared with controls without drug expo-
sure. Toovey and Jamieson16 found AL treatment to be asso-
ciated with irreversible hearing loss. The mean time between
exposure to AL and post-exposure audiogram was 163.8 days
(range = 3–392 days).16
Among seven single-exposure studies that included audi-
tory assessment before and after treatment, three studies
reported neuroauditory abnormalities after artemisinin treat-
ment.20,27,28 Gurkov and others27 undertook an RCT and
revealed a prolongation of ABR IPLs I–III on day 28 after
a single treatment with AL. This prolongation disappeared
by day 90.27 The study also showed a significant transient
cochlear hearing loss in patients treated with quinine, which
has been previously reported in the literature.27 Carrasquilla
and others20 also conducted an RCT assessing single exposure
to AL, where 2.6% of participants showed a significant pro-
longation of ABR latency of wave III at day 7 after treatment
(the primary outcome was wave III prolongation in ³ 15%
of participants). An additional model-based analysis found no
apparent relationship between the drug exposure and the ABR
changes.20 Finally, during a phase IV single-arm study, Frey and
others28 found that, after a single exposure with artesunate-
mefloquine (AM) in Cameroon, children aged 7 months old to
7 years old were reported to experience a transient drug-related
mild to moderate neurological or neuropsychiatric impairment
that resolved spontaneously. Eleven events in 8 of 213 children
(5.16%) were considered to be related to the study medica-
tion28; the most common events were vertigo, dizziness, head-
ache, and sleeping disorders. 28 The study could not rule out that
this finding was attributable to mefloquine alone, and despite
assessing neurological safety in children below 5 years old, Frey
and others28 did not perform any auditory examination.
Lacking meta-analysis options, we summarize the current
available ACT neuroauditory safety data according to the
Oxford Center of Evidence Based Medicine (OCEBM) levels
of evidence (Table 5). Grades B and C of evidence can be
inferred uniquely from studies that tested older age groups
(over 5 years old and particularly, young adults). However, in
the under 5 years old age group, evidence gaps remain sig-
nificant and cannot be graded.
DISCUSSION
This review is the first comprehensive and systematic review
on specific human neuroauditory safety concerns of ACTs for
the treatment of uncomplicated malaria since these concerns
were raised a decade ago. Unfortunately, this review reveals a
lack of collective effort to obtain the required safety data in a
structured way, although ACTs have become some of the
most widely used drugs in Africa over the past decade.
This review highlights the technical challenges involved in
determining this specific safety concern properly, but more
importantly, it questions if the scientific community has
Figure 2. Descriptive overview of included studies. a Four retrospective studies. b Prospective study. *Only 98 cases in total were children < 5 years
of age.
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Table 3
Summary table of main data extracted
Study Study design Participants and location Neuroauditory methods Neuro-ototoxic end points
Multiple exposures (seven studies; including children < 5 years)
Kissinger and
others, 200017
Case-control. Cases
(N = 350): Ar/As
(N = 242), MQ (N = 10),
ArMQ (N = 98). Controls
match age/sex (N = 108).
ME range in the group
(1–21), Retrosp
1–65 years; 96 cases < 5
years (compared with
published normative
data, because only 2
controls were < 5
years); Vietnam
Neurological examination,
otoscopy, audiometry, ABR
(80 dB). Patients exposed
£ 2 years ago. Time since
last Rx not reported.
Abnormalities in hearing,
vestibular and cerebellar
function. Intensity of drug
exposure (milligrams per
kilogram) effect on ABR;
PTA: dB threshold at £ 30
to > 60 dB from 500 Hz t
500Hz–8kHz 8 kHz (4 kHz);
ABR: IPLs I–V, I–III, and
III–V (milliseconds). In
ABRs, the equipment
accuracy was 0.1
milliseconds; below this
variation, no significance; >
2.5 SD of normative data
mean for age was
considered abnormal.
Van Vugt and
others, 200026
Case-control. Cases (N = 79).
Oral Ar or As ³ 2 in last
3 years. Controls match age/
sex (N = 79). ME range per
case (2–9), Retrosp
3–53 years (< 5 years;
N = 2); Thailand
Neurological examination,
audiometry, ABRs
(80 dB). Median time
(range) from most recent
exposure was 385 days
(31–1,963 days)
Abnormalities in neurological
assessment (Romberg’s test,
tandem test, fine-finger
dexterity, eye movements,
behavior); PTA: decibel
hearing threshold (0.5–
8 kHz); ABR: I–III, I–V,
III–V IPLs (milliseconds)
Adjei and others,
200823
RCTAS-AQ (N = 116) vs. LA
(N = 111; 1-year follow-up).
ME (?). Incidence rates of
0.37 in AS-AQ and 0.34 in
LA, Prosp, Pre-Rx
6 months to 14 years;
Ghana
Neurological examination;
PTA only in ³ 5 years
(N = 72: AS-AQ = 37;
LA = 35); on days 0, 3, 7,
and 28 and 1 year after
Abnormalities in neurological
assessment; PTA: decibel
hearing thresholds (0.125–
8 kHz)
Maiteki-Sebuguzi
and others, 200824
RCT UM repeated Rx
AQ-SP (N = 129) vs.
AS-AQ (N = 133), LA
(N = 120). ME (?), Prosp
1–12 years; Uganda Neurological examination
with hearing assessment
(assessment not mentioned)
and fine-finger dexterity on
days 0, 1, 2, 3, 7, and 14
No neuro-ototoxic end points
Multiple exposures (not including children < 5 years)
Toovey and
Jamieson, 200416
Case-control in subjects
working at a construction
site. Cases (N = 150) LA.
Controls match age, sex,
weight, race (N = 150).
ME (?), Retrosp
18–72 years;
Mozambique
Audiometry taken at the
beginning of project and
nearly 2 years after. Mean
time (range) between
exposure to LA and post-
exposure audiogram was
163.8 days (3–392 days)
Audiometry decibel hearing
thresholds(0.25–8 kHz)
Hutagalung and
others, 200619
Case-control. Cases (N = 68)
Rx more than one time with
AL in past 5 years. Controls
(N = 68) match age/sex. ME
(?), Retrosp
7–65 years; Thailand Tymp, PTA, ABR (80 dB).
Median time (range)
between exposure and
audiometry testing was
33 months (20–58 months)
Tymp: MEP (decapascal;
< 150 daP excluded); PTA:
decibel hearing threshold
(0.25–8 KHz). Mild,
moderate, and severe
hearing loss if ³ 25, ³ 30, and
³ 35 dB, respectively, at any
tested frequency; ABR: I–
III, III–V, and I–V IPLs
(milliseconds). Difference >
0.30 milliseconds was
considered physiologically
significant.
Ndiaye and
others, 201125
RCT, open label with ME to
AS-AQ (N = 184) vs. LA
(N = 182). ME (?), Prosp,
Pre-Rx
9.6 months to 65 years;
Senegal (no specific
neurological or
auditory assessment in
individuals
< 5 years)
Audiograms after all malaria
episodes on days 0, 3, and 28
(if any abnormality were
detected on day 3);
audiograms only in
³ 12 years
Difference in decibel
thresholds obtained for
each ear and octave range
(5–16 kHz) on days 0 and 3
(day 28 if abnormalities
are detected).
Single exposures (eight; including children < 5 years)
Abdulla and
others, 200841
RCT, single blind, multicenter
Lad (N = 447) vs. LA
(N = 452). SE, Prosp
0–12 years, ³ 5 kg; Benin,
Kenya, Mali, Tanzania,
Zanzibar, Mozambique
Neurological examination;
reported hearing loss
by children
No auditory end points
(continued)
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TABLE 3
Continued
Study Study design Participants and location Neuroauditory methods Neuro-ototoxic end points
Ambler and
others, 200947
RCT, open label, single center,
neurological safety of As-
MQ (N = 46) or As mono
(N = 45). Non-febrile
control children (N = 36).
SE, Prosp. Pre-Rx
3 months to 5 years;
Thailand
Neurological examination
(coordination + behavior),
hand coordination-adapted
Griffith’s Scales +
Movement ABC, tone and
behavior—Hammersmith,
Bayley
No auditory end points
Frey and others,
201028
Phase IV, open-label, single-
arm study assessing the
neurological and
neuropsychiatric safety of
As-MQ (N = 220). SE,
Pre-Rx
7 months to 7 years + 9
months (10–20 kg);
Cameroon
Neurological and
neuropsychiatric
examinations on days 0, 7,
28, and 63 (Q to guardian,
Q to child, investigator
observations, and 12 clinical
examinations based on
Touwen paeds neurological
examination)
Questionnaires and
examinations covered
hearing loss and acoustic
acuity. Not specified end
points apart from intensity
of adverse events,
frequency, age distribution,
onset, and resolution.
Single exposures (not including children < 5 years)
McCall and
others, 200618
Cohort, volunteers (N = 15)
undergoing experimental
malaria infection and Rx
LA. SE, Prosp, Pre-Rx
18–23 years (malaria-
naı¨ve); The
Netherlands
Tymp day 0, DP-OAE day 0;
PTA (standard + high
frequency) days 0, 8, 21/22;
ABR (70 dB) days 0 and
21/22
Tymp: MTC (milliliters) +
MEP (decapascal); OAE:
DP thresholds; PTA:
decibel hearing thresholds
(0.25, 0.5, 1–16 kHz); ABR:
I–V IPLs (milliseconds) + I,
III, and V peak latencies+ V
peak ABR auditory
thresholds. Latencies
prolonged > 2 SD from
baseline and decibel
threshold deteriorations
³ 10 dB
Carrara and
others, 200848
Safety study (N = 161; N = 93
in final analysis) assessing
auditory functions in
patients UM As-MQ day 0
(pre) vs. 7. SE, Prosp,
Pre-Rx
13–53 years; Thailand–
Myanmar border
Otoscopy, tymp, audiometry,
ABR (80 dB)
Tymp: MEP < −150 daP or flat
wave or a wave peak with
oscillations (were excluded);
PTA: decibel hearing
thresholds (0.25–8 kHz) >10
dB between days 0 and 7;
ABR: wave III latency
(milliseconds) was the
primary end point
(difference > 0.3
milliseconds between days 0
and 7)
Gurkov and
others, 200827
RCT, open-label LA (N = 30)
vs. Q (N = 35), AP (N = 32).
SE, Prosp, Pre-Rx
6–50 years (not exposed
to artemisinin before);
Ethiopia
Audiovestibular tests, PTA,
TE-OAE, DP-OAE, ABR
(80 dB)
Clinical data: no pre-defined
clinically relevant end point;
PTA: decibel hearing
thresholds by air (0.125–
8 kHz) and bone conduction
(0.25–6 kHz). Difference in
means of 5 dB between
groups assumed as common
SD; TE-OAE: pass vs. fail;
DP-OAE: DP thresholds;
ABR: I–III, III–V, and I–V
IPLs (milliseconds)
Benjamin and
others, 201246
RCT, single-center, single-
dose ART-NQ + water
(grade 1, N = 15), single-
dose ART-NQ + milk
(grade 2, N = 17), or
two daily doses + water
(grade 3,N = 16). SE, Prosp,
Pre-Rx
5–12 years; Papua New
Guinea
PTA (grade 1), Whispered
voice test (grades 2 and 3).
Rinne’s and Weber’s test
(grades 2 and 3); hearing
tests: day 0 (4 hours) and
days 1, 7, and 28. No
mention of additional
neurological assessments
PTA: Difference in decibel air
conduction thresholds at
³ 25–40, 41–55, 56–70 (0.25–
8 kHz), and. 71–90 dB.
Whispered voice test:
repetition of at least three
of six numbers/letters
corrected
Carrasquilla and
others, 201220
RCT, open-label, single-
center, LA (N = 159), AP
(N = 53) vs. AM (N = 53).
SE, Prosp, Pre-Rx
12–56 years; Colombia Tymp, otoscopy, ABR, PTA
days 0 (pre-Rx), 3 (1 hour
after last Rx dose), 7, 28,
and 42
Primary outcome: ³ 15%
patients with a day 7 wave
III latency increase > 0.30
milliseconds after LA
ABC = assessment battery for children; AP = atovaquone-proguanil; Ar/As = artemisinin or artesunate; ArMQ = artemisinin + mefloquine; ART-NQ = artemisinin-naphtoquine;
AS-AQ = artesunate-amodiaquine; AQ-SP = amodiaquine-sulfadoxine-pyrimethamin; DP = distorsion product; LA = lumefantrine-artemether; LAd = LA dispersible; ME = multiple
exposure; MEP = middle ear pressure; MQ = mefloquine alone; MTC = maximum tympanic compliance; pre-Rx = pre-treatment assessment; Prosp = prospective; Q = quinine; Retrosp =
retrospective; Rx = treatment assessment; SE = single exposure; TE = transient-evoked; Tymp = tympanometry; UM = uncomplicated malaria; ? = not reported.
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neglected the opportunity and its responsibility for ongoing
targeted assessment of the safety of widely used antimalarials
in real-life settings during the post-marketing period. Most of
the studies aimed to assess efficacy and general safety of a
single exposure. Only 15 studies looked at specific neuro-
auditory and/or general neurological safety outcomes. The
lack of a standardized approach to drug adverse event moni-
toring hampered the ability to compare data collected in dif-
ferent studies and prevented any meaningful meta-analysis.
Systematic assessments for adverse events in efficacy–safety
studies generally followed the International Conference of
Harmonization Good Clinical Practice guidelines. These assess-
ments, however, did not focus on the existence of system-
specific adverse events and could not rule out neuroauditory
toxicity of ACTs in humans. The reviewed studies that were
looking at multiple and single exposures to ACTs identified
some changes in the hearing assessments performed after
treatment but collectively failed to accurately and objectively
Table 4
Summary of main study results
Study Relevant results
Multiple exposures
Kissinger and others, 200017 Neurological examination: no abnormalities among examined subjects (81.5% of subjects). Otoscopy:
28% had pus or perforation. ABR: in ³ 5 year olds, very small but significant difference in I–V
(3.82 vs. 3.74 milliseconds, P = 0.007) and I–III IPLs (2.03 vs. 1.98 milliseconds, P = 0.0027) of right
ear (longer) in cases vs. controls. In < 4 year olds (compared with normative data), only one patient
had an IPL > 2.5 SD from the mean for the age (the child also had pus in the external auditory canal).
Effect of total drug exposure: IPLs I–III (2.07 vs. 2.00 milliseconds, P = 0.014) and I–V (3.89 vs. 3.79
milliseconds, P = 0.014) of the right ear of cases with higher cumulative dosage (> 500 mg/kg) vs.
(£ 500 mg/kg) Ar/As cumulative dosage. However, when correcting for age, no significant
differences regarding cumulative dosage in IPLs.
Van Vugt and others, 200026 Neurologic examination: all normal except for hearing test in one case and two controls (PTA and
ABR). Very small but significant difference between controls and cases (longer; 2.08 vs. 2.14
milliseconds; SD = 0.19) for the IPLs I–III only in the right side (P = 0.049). No correlation between
the total dose (milligrams per kilogram) of artemisinin administered and IPLs.
Adjei and others, 200823 Neurologic examination: no abnormal findings in children without previous pathologies. PTA: hearing
thresholds significantly elevated in treated children on days 0, 3, 7, and 28 but not at 9–12 months.
No additional details.
Maiteki-Sebuguzi and others, 200824 Neurological examination: children < 5 years who received AQ-SP were at higher risk of anorexia
(RR = 3.82, 95% CI = 1.59–9.17, P = 0.003) and weakness (RR = 5.40, 95% CI = 1.86–15.7, P = 0.002)
than those children treated with AL. No reported results on hearing loss.
Toovey and Jamieson, 200416 PTA: hearing threshold loss was significantly greater in the treatment group at all except the very
lowest frequencies of 250 and 500 Hz. The mean threshold change was negative in the treatment
group, ranging from −6.50 dB (95% CI = −8.19 to −4.81) to −0.07 dB (95% CI= −2.19–2.05).
Hutagalung and others, 200619 High proportion of subjects with hearing loss overall related to age. PTA: no differences between the
groups in MEP and the median PTA conduction thresholds. ABR: no differences in wave length
or the IPLs.
Ndiaye and others, 201125 Audiograms in 167 patients during the first malaria episode and 12 patients during the second episode.
Hearing thresholds on days 3 and 28 showed no significant variation compared with pre-Rx on day 0
and no difference between AS-AQ and LA.
Single exposures
Abdulla and others, 200841 Neurological examination: isolated cases of somnolence, convulsion, dyskinesia, epilepsy, dizziness,
and tremor reported as unrelated adverse events. No patient reported hearing loss.
Ambler and others, 200947 Neurological examination: coordination, behavior, and tone not significantly changed by either treatment.
Frey and others, 201028 Neurological and neuropsychiatric examinations: among 213 children, 3.8% of the children had a
transient drug-related mild to moderate neurological or neuropsychiatric impairment, which
resolved spontaneously. The most common neurological disorders were sleeping disorders,
insomnia, nightmares, vertigo, dizziness, and headache. No report on hearing impairment.
McCall and others, 200618 Tymp, OAE, PTA, ABR: no prolongations of peak latencies or I–V IPLs were seen. No statistically
significant differences after the treatment (day 8 for PTA and day 21/22 for ABR + PTA) compared
with before the infection.
Carrara and others, 200848 Hearing loss on admission was common (57%) and associated with age. Day 7 vs. 0 showed no
threshold change > 10 dB and no shift in wave III latency > 0.30 milliseconds.
Gurkov and others, 200827 PTA and DP-OAE revealed transient significant cochlear hearing loss in patients treated with Q on
day 7 that disappeared on day 28. ABR: the prolongation of I–III IPLs between LA and the other
groups on day 28 disappeared by day 90 (only right ear). In all groups, IPLs I–Vwas shorter on day 0.
One patient in the LA group had a potentially clinically relevant interaural difference of IPLs I–III
> 10% on day 28 (disappeared by day 90).
Benjamin and others, 201246 PTA: At baseline, children had normal or mild hearing loss (³ 25–40 dB) with no subsequent changes
on audiometry over time in group 1 (P > 0.05). In groups 2 and 3, 76% of children cooperated with
the tests. Whispered test, audiovestibular tests: no abnormalities were detected by any of the tests at
baseline or subsequently.
Carrasquilla and others, 201220 ABR: 2.6% of patients on LA (95% CI = 0.7–6.6) exceeded 0.30 milliseconds at day 7 wave III latency,
statistically significant below 15% (P < 0,0001). No patient receiving AM or AP revealed day 7 III
IPLs increases of > 0.30 milliseconds. None of the latency increases were sustained, bilateral, or
associated with significant PTA thresholds deteriorations. PTA: no notable changes were observed
for any treatment group at any frequency. A model-based analysis found no apparent relationship
between drug exposure and ABR change.
CI = confidence interval; RR = relative-risk.
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investigate this finding, particularly in children under 5 years
of age, most likely for very pragmatic reasons.
The investigation of hearing impairment in infants and
young children can be particularly challenging, especially when
trying to detect subtle and early toxicity in remote settings
where trained audiologists and equipment are not available.
There is a need to provide objective auditory measurements
to predict the pure tone audiogram in young children that
cannot report reliable behavioral responses to sound. OAEs
and/or ABRs are widely used to detect sensory or conductive
hearing loss in this age group (Joint Committee on Infant
Hearing, unpublished data). ABR measurements are particu-
larly well-suited in detecting and estimating a magnitude of
hearing loss in young children, with click-evoked ABRs pro-
viding several advantages: they assist in determining whether
auditory neuropathy exists and can be obtained in a relatively
brief amount of time.29 However, ototoxicity tends to start at
high frequencies (8–12 kHz) before speech frequencies are
affected.13 Because conventional ABR only explores speech
frequencies of 1–4 kHz, it does not detect early ototoxicity
before clinical significance. The studies by McCall and others18
and Ndiaye and others25 were the only studies to explore fre-
quencies over 8 kHz, but they involved only 12 adult patients
with a single treatment of experimental human malaria and
only participants ³ 12 years old after two exposures (on day 0
before dosing, day 3, and if abnormality was detected, day 28),
respectively. Neither study provided a definitive answer about
ACT safety at high frequencies.18,25
The variations in study designs and auditory assessment
methods used (Table 3) prevented systematic investigation of
an association between neuroauditory changes and ACT use.
Studies that showed impaired auditory assessments in older
children, adolescents, and adults generally failed to explore
the association in detail and did not examine adequately the
presence of possible confounding factors. Single-exposure
studies in Ethiopia and on the Thailand–Burma border, which
performed pre-treatment hearing assessments to account for an
influence of malaria on hearing impairment, were reassuring in
their conclusions but lacked evidence. In both studies, similar
improvements on hearing were detected 7 days after treatment
that were correlated to a learning effect (with the use of behav-
ioral audiometric assessments) or a fever resolution, but they
failed to show or rule out an association and potential ototoxic
effect of the drugs.19,27 However, the study that raised the
safety concern on humans and opened a global safety discus-
sion of ACTs reported an association between artemether and
irreversible hearing impairment in construction workers. Nev-
ertheless, the study could not establish if the association was
caused by the drug, the malaria episode, or the prolonged
occupational noise exposure of the study participants.16
Causes of hearing damage are multifactorial, and therefore,
potential confounders need to be taken into account. A chal-
lenging one in this context is the potential disease-specific
damage caused by malaria itself. Hearing loss is a recognized
complication of cerebral malaria,30 but the evidence regard-
ing an association between uncomplicated malaria and hear-
ing impairment remains inconclusive. Some authors have
hypothesized that the presence of malaria may contribute to
hearing loss by lowering resistance to ototoxic drugs or vascular
disruption in the end arteries of the cochlea.31,32 A recent
study has assessed the impact of malaria on hearing in mice.
ABRs were performed before the infection and at the peak of
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the disease (between days 5 and 11 after the infection without
the administration of antimalarials). Hearing impairment was
found in mice with both cerebral and uncomplicated malaria
compared with a control group that was not infected with
malaria.33 There is also real potential for confounding by
ototoxic effects of the partner drug in the ACT, especially
from quinoline-based drugs such as mefloquine, piperaquine,
and amodiaquine. Mefloquine, in particular, is recognized as a
central and peripheral neurotoxic, with several human reports
documenting a range of neuropsychiatric effects as well as
both reversible and irreversible hearing loss when used at
prophylactic concentrations in adult patients.34,35 The periph-
eral ototoxicity of mefloquine follows a dose-dependent
mechanism of cochlear hair cells and spiral ganglion neurons
loss different from the artemisinin derivatives.36 However,
animal models and a recent human case report have provided
additional insight into the clinical significance and plausible
pathophysiology of mefloquine focal brainstem, limbic, and
thalamic cortical toxicity that needs to be emphasized and
further elucidated when investigating the potential neurotoxic-
ity of ACTs.37,38 Cognizant of this information, the US Food
and Drug Administration announced label changes for the
approved mefloquine hydrochloride in July of 2013 to specif-
ically warn of the risk of permanent neurological effects,
including vestibular symptoms and tinnitus.39
Neuroauditory events could be associated with the use of
cumulative high-dose exposure in young children, and more
emphasis needs to be given to the potential of dose- and age-
dependent adverse events. Drugs are assessed at very narrow
dose ranges during the drug development stages, and consid-
erable developmental changes in early childhood affect the
pharmacokinetic profile of drugs. With the current recom-
mended weight-based dosing regimens in sub-Saharan Africa,
children under 5 years of age could receive oral artemether
ranging from 2 to 6 mg/kg per dose and from 8 to 24 mg/kg per
course of treatment.40 In settings where age-based dosing reg-
imens are used (e.g., treatment by village health workers or in
health centers that do not have functional scales), children
can be exposed to > 5 mg/kg per dose. These unintended high
doses could have a detrimental neuroauditory impact that has
not yet been investigated. Better knowledge and targeted
studies to determine safety around the upper therapeutic
intake dose threshold are urgently needed to support their
programmatic use, including the development of evidence-
based age-based regimens.
The main limitations of this review are the varying quality
and descriptive nature of the neuroauditory findings reported
by most studies and the lack of robust data from the most
vulnerable groups. The risk of bias was unclear or likely for
the majority of studies. Of the RCTs, only the study by
Abdulla and others41 showed a low risk of bias in selective
reporting of results. The others were classified as unclear risk
of bias in this item, because safety end points were reported as
secondary results without detail (Table 2). To summarize our
findings, we present a summary table of results (Table 5) graded
according to widely used medicine-based evidence levels
(OCEMB) to help identify specific remaining neuroauditory
safety gaps in the most vulnerable populations.42 This informa-
tion highlights two important issues. First, there is a need for
an appropriate standardized method to detect early ototoxicity
and other adverse effects in young children. Second (and more
generic), there is an urgent need to collect and compile study
safety data in a more standardized way, similar to the data com-
pilation and analyses of antimalarial efficacy data conducted by
theWorldwideAntimalarial ResistanceNetwork (WWARN).43
In conclusion, after a decade of use, there remains a lack of
high-quality evidence on the neuroauditory safety of ACTs.
There is no reported evidence to rule out the occurrence of
any ototoxicity in those individuals who have been mentioned
over and over again as the most vulnerable subgroup: young
children who are treated repeatedly during a potentially vul-
nerable phase of brain development and may be exposed to
some of the highest intake doses. Early evaluation and pre-
vention of hearing impairment in childhood are essential,
because hearing impairment can have severe adverse effects
on speech, behavior, linguistic understanding, and language
acquisition, contributing to global disability and mortality.
Early-onset hearing loss detection programs are successful
and increasingly implemented in the developing settings.44
More efforts should be made to improve this evaluation
through not only universal infant hearing screening programs
but also, monitoring of neuroauditory adverse events from
potential ototoxic agents that are given repeatedly over time.
With the current exploration of the use of ACTs for mass
drug administration programs (conducting multiple full treat-
ment courses per year) in an attempt to reduce transmission
and the potential need to increase artemisinin dosing in the
near future to slow the spread of emerging artemisinin resis-
tance, this knowledge gap should not merely be accepted after
a decade of widespread use but addressed as soon as possible.
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